Assignee
ALTO NEUROSCIENCE INC
US·5 granted patents·18 pending applications·0 citations·filing 2022–2025
Top patents by PatentIndex Score
23 records- 0182US12521374B1Combination therapy for a dopamine agonistALTO NEUROSCIENCE INC·Filed 2025·Granted Jan 13, 2026·0 cites·19 claims
- 0282US2026069573A1Combination therapy for a dopamine agonistALTO NEUROSCIENCE INC·Filed 2025·Application pending·0 cites
- 0378US12233059B2Effective treatment of depression in patients having impaired learning and/or memory or certain EEG characteristics with a benzylpiperazine-aminopyridine agentALTO NEUROSCIENCE INC·Filed 2024·Granted Feb 25, 2025·0 cites·20 claims
- 0475US12208096B2Effective treatment of depression in patients having impaired learning and/or memory or certain EEG characteristics with a benzylpiperazine-aminopyridine agentALTO NEUROSCIENCE INC·Filed 2024·Granted Jan 28, 2025·0 cites·12 claims
- 0572US12226375B1Method of treatment and selection of patients benefiting from agomelatine based on EEG measurementsALTO NEUROSCIENCE INC·Filed 2024·Granted Feb 18, 2025·0 cites·17 claims
- 0670US2025009738A1Effective treatment of depression in patients having impaired learning and/or memory or certain eeg characteristics with a benzylpiperazine-aminopyridine agentALTO NEUROSCIENCE INC·Filed 2024·Application pending·0 cites
- 0769US2024307377A1Method of treatment of depressed patients with poor cognition and selection of other patients benefiting from a benzylpiperazine-aminopyridine agentALTO NEUROSCIENCE INC·Filed 2024·Application pending·0 cites
- 0864US2024307376A1Method of treatment of depressed patients with poor cognition and selection of other patients benefiting from a benzylpiperazine-aminopyridine agentALTO NEUROSCIENCE INC·Filed 2024·Application pending·0 cites
- 0964US2025144092A1Treatment of psychiatric or neurological disorders in patients with prominent anhedonia using irdabisant as a monotherapy or in combination with an antipsychotic agentALTO NEUROSCIENCE INC·Filed 2024·Application pending·0 cites
- 1063US2024316016A1Effective treatment of depression in patients having impaired learning and/or memory or certain eeg characteristics with a benzylpiperazine-aminopyridine agentALTO NEUROSCIENCE INC·Filed 2024·Application pending·0 cites
- 1163US2023117508A1Enhancement of camp signaling as a combination drug strategy for the treatment of psychiatric and neurological disorders in which depressive, anhedonia, motivation-related or cognition-related dysfunction existsALTO NEUROSCIENCE INC·Filed 2022·Application pending·0 cites
- 1262US2025120957A1Treatment of neuropsychiatric disorders with tilivapramALTO NEUROSCIENCE INC·Filed 2024·Application pending·0 cites
- 1361US2024342165A1Method of treatment of depressed patients with poor cognition and selection of other patients benefiting from a benzylpiperazine-aminopyridine agentALTO NEUROSCIENCE INC·Filed 2024·Application pending·0 cites
- 1461US2024307378A1Effective treatment of depression in patients having impaired learning and/or memory or certain eeg characteristics with a benzylpiperazine-aminopyridine agentALTO NEUROSCIENCE INC·Filed 2024·Application pending·0 cites
- 1559US2024197721A1Effective treatment of depression in patients having impaired learning and/or memory or certain eeg characteristics with a benzylpiperazine-aminopyridine agentALTO NEUROSCIENCE INC·Filed 2023·Application pending·0 cites
- 1658US2024342164A1Method of treatment of depressed patients with poor cognition and selection of other patients benefiting from a benzylpiperazine-aminopyridine agentALTO NEUROSCIENCE INC·Filed 2024·Application pending·0 cites
- 1758US2025177387A1Effective treatment of depression in patients having impaired learning and/or memory or certain eeg characteristics with a benzylpiperazine-aminopyridine agentALTO NEUROSCIENCE INC·Filed 2025·Application pending·0 cites
- 1855US2025177386A1Method of treatment of depressed patients with poor cognition and selection of other patients benefiting from a benzylpiperazine-aminopyridine agentALTO NEUROSCIENCE INC·Filed 2025·Application pending·0 cites
- 1954US2022387424A1Method of treatment of depressed patients with poor cognition and selection of other patients benefiting from a benzylpiperazine-aminopyridine agentALTO NEUROSCIENCE INC·Filed 2022·Application pending·0 cites
- 2052US2025177331A1Method of treatment and selection of patients benefiting from agomelatine based on eeg measurementsALTO NEUROSCIENCE INC·Filed 2025·Application pending·0 cites
- 2152US2026060979A1Method for improving neuroplasticityALTO NEUROSCIENCE INC·Filed 2025·Application pending·0 cites
- 2249US2022226331A1Integration of molecular mechanisms in the striatum as a combination drug strategy for the treatment of psychiatric and neurological disorders in which anhedonia or motivation-related dysfunction existsALTO NEUROSCIENCE INC·Filed 2022·Application pending·0 cites
- 2340US12594028B1EEG montage for facilitating selection of drug treatment in patients suffering from psychiatric disordersALTO NEUROSCIENCE INC·Filed 2025·Granted Apr 7, 2026·0 cites·8 claims
Join the waitlist — get patent alerts
Get an alert when ALTO NEUROSCIENCE INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →